secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001558370-24-000013
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics signs commercial manufacturing deal with Thermo Fisher's Patheon for uproleselan
--------------------------------------------------------------------------------

- Agreement covers commercial supply of injectable uproleselan if FDA approves the drug.
- Initial term through Dec 31, 2026, auto-renews for 3-year periods unless terminated.
- Company provides API; Patheon supplies other raw materials, packaging, and QC testing.
- Company gave Patheon a forecast of required annual volumes through 2027.
- Either party may terminate after initial term with 18 months' notice; termination fees apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024000013/0001558370-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024000013/glyc-20240102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer